Results obtained with the CEACAM1, EPHA2 and CEACAM6 analysis in CRC patients therefore validate the experimental model developed with the MC38 and HT29 metastatic cell lines herein, such that high CEACAM1 with low EPHA2 expression along with added interaction of CEACAM6 (in the case of human cells) in poorly differentiated CRC carcinomas constitutes a signature for significantly reduced CRC liver metastasis and overall better outcome. This evidence concerns the gene CEACAM6 and colorectal carcinoma.